Article
2022
Economic Evaluation of a Tumour-Agnostic Therapy: Dutch Economic Value of Larotrectinib in TRK Fusion-Positive Cancers
RE Michels, CH Arteaga, ML Peters, E Kapiteijn, CML Van Herpen, M Krol
Article
2023
Comparative Efficacy of Biologic Disease-Modifying Anti-Rheumatic Drugs for Non-Radiographic Axial Spondyloarthritis: A Systematic Literature Review and Bucher Indirect Comparisons
N. Akkoç, CH Arteaga, SE Auteri, M Betts, K Fahrbach, M Kim, S Kiri, B Neupane, K Gaffney, PJ Mease
Article
2020
Budget Impact Analysis of a Reduced Maintenance Dose of Certolizumab Pegol in Patients with Axial Spondyloarthritis in the United Kingdom
S. Kiri, CH. Arteaga Duarte, N. Lyris, M. Lamotte, L. Gerlier. J Value in Health. Vol 23, Suppl. 2, S412-S413, Dec. 2020
Article
2020
Cost-Effectiveness Analysis of Certolizumab Pegol Versus Secukinumab and Ixekizumab in Non-Radiographic Axial Spondyloarthritis in the U.S.
Kiri S, Arteaga CH, Lee E, Low R, Tsakeu E, Lamotte M, Gerlier L. AMCP-NEXUS Oct. 2020
Article
2019
The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study
Arteaga Duarte CH, Fakra E, Van Gils C et al. L'Encéphale J Clin Psychiatry and Psychopharmacology, December 2019
Article
2018
Setting Evidence-Based Priorities for Universal Health Coverage – Where is the Evidence?
Downey LE, Rao NV, Selvaraju KV, De Francesco M et al. 7th Annual Conference of Indian Health Economics and Policy Association, January 2018
Link coming soon
Article
2018
Core obesity model to assess the cost-effectiveness of weight management interventions
De Francesco M, Lopes S, Meincke HH, Vega G, Lean M, Lamotte M. Value in Health 2018; 21: S454. Poster presentation at ISPOR Europe 2018
Article
2018
Assessing the cost-effectiveness of three-monthly paliperidone palmitate versus its prior monthly formulation for the management of schizophrenia in the UK setting
Arteaga C, Nilforooshan R, Lee J et al. Value in Health 2018. Poster presentation at ISPOR USA 2018
Article
2018
Cost-effectiveness of cladribine tablets for treatment of RRMS in the Netherlands
De Francesco M, Mahajan K, Michels R et al. Value in Health 2018; 21: S339–S340. Poster presentation at ISPOR Europe 2018
Article
2016
Hospital economic burden of HIV and its complications in Belgium
Arteaga CH, Chevalier P. Belgian Research AIDS & HIV Consortium BREACH, 2016. Poster presentation at BREACH symposium 2016
Article
2016
Assessing the cost effectiveness of paliperidone palmitate 3-monthly (Trevicta) in the management of schizophrenia in France
Arteaga CH, Guillon P, Fakra E et al. Poster presentation at ISPOR Europe 2016
Article
2016
Cost effectiveness of allogenic pancreatic islet transplantation versus whole pancreas transplantation in the United Kingdom
De Francesco M, Johnson P, Lamotte M. Value in Health 2016; 19(3): A204. Podium presentation at ADA 76th Scientific Sessions and ISPOR USA 2016
Article
2016
Economic Evaluation of Ipilimumab in First Line Treatment of Advanced Melanoma in Italy
De Francesco M, Lamotte M, Di Rienzo P et al. GRHTA 2016; 3(2): 67–79. Scientific article
Article
2016
Economic impact of contrast-induced acute kidney injury associated with invasive cardiology: role of iso-osmolar contrast media in Germany, Italy, Poland, and Spain
De Francesco M, Ronco C, Wacinski PJ et al. J Med Econ. 2016 Feb;19(2):158-68. Scientific article
Article
2016
Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting
Jugrin AV, Hösel V, Ustyugova A, De Francesco M et al. J Med Econ. 2016 Jan;19(1):1-10. Scientific article
Article
2014
Economic evaluation of intravenous iodinated contrast media in Italy
Iannazzo S, Vandekerckhove S, De Francesco M et al. Int J Technol Assess Health Care. 2014 Jan;30(1):69-77. Scientific article
Article
2013
Impatto sul budget di un trattamento personalizzato dell'epatite B cronica HBeAg-negativa in Italia mediante peg-interferone alfa-2a associato alla stopping-rule alla 12a settimana
Iannazzo S, De Francesco M, Coco B et al. PharmacoEconomics Italian Research Articles. 2013, 15(3):123-130. Scientific article
Article
2013
A review of cost-effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
Iannazzo S, De Francesco M, Gomez-Ulloa D et al. Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):455-68. Scientific article
